ZB

Zura Bio Limited

ZURA·NASDAQ

$4.10

-5.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$266.59M
EPS-1.0600
P/E Ratio-4.97
Earnings Date08/13/2026

zura

Common Stock

Last Annual Value

7.00K

3-Year CAGR

%

5-Year CAGR

-86%

10-Year CAGR

-63%

ZB

Zura Bio Limited Competitors Analysis of Common Stock

ZURA · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
7.00K
20.5%-86.2%N/A 
63.00K
11.9%14.5%N/A
9.00K
4.0%8.4%N/A
2.20K
9.9%-47.8%N/A
15.00K
71.0%49.6%0.0%
4.00K
10.1%5.9%N/A
0.00
N/AN/AN/A
64.65K
30.2%19.7%N/A
21.00K
44.2%39.3%N/A
3.00K
14.5%24.6%N/A
16.00K
47.4%-19.7%-0.7%
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.1, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $4.1